

LTR Pharma Signs National Pharmacy Distribution Agreement with Symbion

22 January 2025

Highlights:

- Symbion, one of Australia's largest pharmaceutical wholesalers, serves over 3,900 pharmacy customers nationwide
- Agreement enables nationwide distribution of SPONTAN® via Symbion's extensive network
- Operational integration targeted for rollout in Q2 2025
- Partnership supports LTR Pharma's early access scheme and lays the foundation for future commercial launch

LTR Pharma Limited (ASX:LTP) ("LTR Pharma", "the Company") is pleased to announce it has entered into an agreement with [Symbion Pty Ltd](#) ("Symbion"), a leading pharmaceutical wholesaler in Australia, to establish national distribution capabilities for SPONTAN®.

Under the agreement, Symbion will provide warehousing, inventory management and nationwide distribution services for SPONTAN through its extensive network of distribution centres servicing over 3,900 pharmacies across Australia. The non-exclusive agreement commences on 1 March 2025 and includes comprehensive quality assurance, inventory management systems and specialised handling processes tailored to pharmacy requirements.

Key implementation milestones include:

- Integration of ordering and inventory management systems
- Establishment of quality control and product handling protocols
- Setup of storage facilities across Symbion's national network
- Implementation of TGA-compliant tracking and documentation systems
- Development of pharmacist education and product support materials

This partnership grants LTR Pharma access to established, scalable pharmaceutical infrastructure, aligning with the Company's strategy to support the early access scheme and prepare for a full-scale commercial launch post-regulatory approvals.

LTR Pharma Chairman, Lee Rodne commented: *"Partnering with Symbion is a pivotal step in building our commercial infrastructure. Symbion's extensive distribution network and expertise will ensure seamless access to SPONTAN across Australia. This agreement underscores our commitment to collaboration with industry leaders to establish a reliable supply chain, support the TGA's early access program, and prepare for SPONTAN's anticipated commercial launch. Together, we are ensuring the highest standards of pharmaceutical handling and service delivery."*

-Ends-

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is focused on improving men's health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma's lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

For further information please contact:

Media enquiries
Haley Chartres
haley@hck.digital

Investor enquiries
Peter McLennan
investors@ltrpharma.com